Tacrolimus Market 2019 Exclusivity, Size, Share, Growth, Value, Trends, Segmentations, Top Mergers, and Forecast 2026
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Tacrolimus, also known as fujimycin or FK506, is an immunosuppressant drug that is used after organ transplant procedures to prevent organ rejection. The drug acts by obstructing the activation of serine-threonine phosphatase, calcineurin, in T lymphocytes. This in turn hinders activation of T lymphocyte and halts the production of cytotoxic lymphocytes that otherwise nay lead to organ rejection. Tacrolimus is used in kidney and liver transplant. Organ transplanted patients often rely on immunosuppressant therapy during their lifetime. Tacrolimus is used for the treatment of heart transplant rejection, liver transplant rejection, kidney transplant rejection, and lung transplant rejection. The drug can be administered in various dosage forms such as tablets, capsules, and injections.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2298
Increasing number of organ transplants is expected to augment the market growth for tacrolimus
Increasing technological advancements in organ transplant procedures is expected to aid in high adoption of the approach, thereby increasing demand for tacrolimus over the forecast period. Major institutes are focused on R&D of new methods to match more donor organs with patients. These activities include stem cell studies, trophic factor studies, and natural models. Increasing demand for organ transplant and its high unmet demand has led to focus on successful utilization and transplantation of available donor organs. For instance, according to Organ Procurement and Transplantation Network (OPTN) 117,000+ number of men, women, and children are on the national transplant waiting list as of July 2017 in the U.S. and 17,155 organ transplants are done so far in 2017. Moreover, according to National Kidney Foundation as of 2016, 121,678 people are waiting for lifesaving organ transplants in the U.S., of which 100,791 people are waiting for kidney transplants.
Better understanding of immunology has increased matching rates for organs and patients after transplants, which also helps in high adoption of organ transplant, thereby aiding the global tacrolimus market growth over the forecast period.
However, significant gap between demand and supply of transplant organs is a major factor hampering growth of the global tacrolimus market. Use of tacrolimus is also associated with certain side effects such ad malignancy, Psychosis, and others, which is expected to hinder the market growth to some extent.
Request for an in-depth table of contents for this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/2298
North America tacrolimus market is expected to account for the largest market share in the global tacrolimus market
On the basis of region, the global tacrolimus market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North America is expected to hold dominant position over the forecast period, owing to high presence of major market players and increasing number of organ transplant procedures. Key players in the market are focused on developing generic version of tacrolimus. For instance, Strides Arcolab received the U.S. Food & Drug Administration (FDA) approval for tacrolimus capsules to be used as immuno-suppressant in 2014. Sandoz launched Tacrolimus, a generic version of Astellas’s PROGRAF (tacrolimus) in Japan, in 2015. Moreover, The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for tacrolimus’ generic, Tacforius in 2017.
Tacrolimus Market Key Players
Major players operating in the global tacrolimus market include, GlaxoSmithKline Plc., Takeda Pharmaceuticals Company Ltd., Abbott Laboratories, Novartis International AG, Mylan N.V., Astellas Pharma, Inc., Senju Pharmaceutical Co. Ltd., Guike Pharmaceutical Co. Ltd., DR. Reddy’s Laboratories Ltd., and Glenmark Pharmaceuticals Ltd.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2298
Tacrolimus Market Taxonomy:
The global tacrolimus market is segmented on the basis of product type, application, end-user, and region
By Product Type:
- Tacrolimus Capsules and Tablets
- Tacrolimus Ointment
- Tacrolimus Injection
By End User:
- Organ Transplant Centers
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire